NDSN · Q4 2025 Earnings

Cautious

Nordson Corporation

Reported December 10, 2025

30-second summary

30-second take: Nordson closed FY2025 with Q4 revenue of $752M (+1% YoY) and non-GAAP EPS of $3.03, with Medical and Fluid Solutions +9.6% offsetting Industrial Precision Solutions -1.5% and Advanced Technology Solutions -3.6%. FY2026 guidance of $2.83–2.95B revenue (+1–6% YoY) and $10.80–11.50 EPS (+6–12%) confirms management's "trough is behind us" thesis but at a pace that barely improves on FY2025's +3.8%. EBITDA margin held at 34% and FCF conversion hit 128% — the operational story remains intact; the demand story is still waiting on a real inflection.

Headline numbers

EPS

Q4 FY2025

$3.03

Revenue

Q4 FY2025

$0.75B

+1.0% YoY

Gross margin

Q4 FY2025

56.3%

Operating margin

Q4 FY2025

28.5%

Key financials

Q4 FY2025

Metric	Q4 FY2025	YoY	Q3 FY2025	QoQ
Revenue	$0.75B	+1.0%	$0.74B	+1.4%
EPS	$3.03	—	$2.73	+11.0%
Gross margin	56.3%	—	54.8%	+150bps
Operating margin	28.5%	—	25.3%	+320bps

Guidance

Company reaffirms FY2025 performance and guides FY2026 revenue growth of 1–6% YoY and adjusted EPS growth of 6–12% YoY, signaling modest top-line recovery with margin expansion as end-market inflections begin.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q4 FY2025	slightly below the midpoint of full year sales guidance	$752 million	in-line	Met
Adjusted EPS	Q4 FY2025	slightly better than midpoint of full year guidance	$3.03 non-GAAP	above guidance	Beat

New guidance

Metric	Period	Guide	YoY
Revenue	FY2026	$2,830 to $2,950 million	+1% to +6% YoY
Adjusted EPS	FY2026	$10.80 to $11.50	+6% to +12% YoY
Revenue	Q1 FY2026	$630 to $670 million	—
Adjusted EPS	Q1 FY2026	$2.25 to $2.45	—

Segment KPIs

Q4 FY2025

Segment	Q4 FY2025	YoY
Industrial Precision Solutions	$0.362B	-1.5%
Medical and Fluid Solutions	$0.22B	+9.6%
Advanced Technology Solutions	$0.171B	-3.6%
Industrial Precision Solutions EBITDA Margin	37.9%	—
Medical and Fluid Solutions EBITDA Margin	39.8%	—
Advanced Technology Solutions EBITDA Margin	25.1%	—

Other KPIs

Q4 FY2025

Segment	Q4 FY2025	YoY
Americas	$0.331B	+2.4%
Europe	$0.195B	+5.4%
Asia Pacific	$0.226B	-4.4%
EBITDA	$256 million	—
EBITDA Margin	34.0%	—
Operating Margin	28.5%	—
Free Cash Flow Conversion	128%	—
Backlog	~$600 million	—

Management tone

Narrative arc: Q2 ATS reacceleration + IPS restructuring → Q3 multi-segment trough call → Q4 "headwinds behind us" optimism despite organic give-back.

Three quarters ago IPS was being actively restructured for >$15M of 2026 savings while management waited for demand to return. Two quarters ago they called the trough explicitly ("we believe this business has hit its trough"). This quarter, with IPS still printing -1.5% YoY, management escalated to declaring "key market headwinds behind us" and pointing to polymer processing and industrial coding as "no longer a drag." The verbal escalation is running ahead of the segment numbers — IPS hasn't actually inflected, it has merely stopped falling further. The +1–6% FY26 sales guide quietly concedes this; management is optimistic about direction but conservative about magnitude.

ATS framing completed a full cycle from "lumpy" caveats to confirmation of that lumpiness. Last quarter management preemptively warned that "demand in this business inherently is lumpy" and flagged Q4 comp risk. Q4 delivered -3.6% YoY, validating the caveat. The forward pitch is now anchored on semiconductor exposure (50% of ATS revenue) tied to AI/cloud — the Moran/Hammond exchange confirmed Q1 ATS growth will benefit from favorable YoY comps after a soft Q1 FY2025 start. The new "Q1 strong" framing therefore depends partly on a base effect, not pure demand strength.

Medical destocking moved from "severity reducing" (Q2) to "now fully behind us" (Q4), with the interventional business explicitly back to "mid-single digit organic growth." This is the cleanest cross-quarter resolution in the file. The CDMO divestiture is expected to add ~100bps to medical segment margins in FY26 per the DA Davidson exchange, though management cautioned the Q4 40%+ print is not the new normal.

M&A tone shifted from "Atrion accreted a year ahead of plan" energy in Q3 to a flat "no actionable deals met both strategic and financial criteria in 2025" admission in Q4. The pipeline is described as healthy but management explicitly named ~$250 buybacks as "actionable" given a recent authorization increase. Read this as a quiet signal that capital return — not acquisitions — is the most likely near-term deployment lever.

The overall posture is unusually optimistic for a company that just posted organic sales declines in two of three segments. As the tone extraction put it: management is "front-running visibility into demand recovery rather than waiting for confirmed results."

Recurring themes management leaned on this quarter:

Portfolio optimization through divestiture improving margin profileDestocking completion signaling demand normalizationSemiconductor cycle positioning as growth catalystCash conversion strength enabling shareholder returnsAscend strategy delivering EBITDA growth consistencyMarket stabilization after year of macro volatility

Risks management surfaced:

Lumpiness in ATS revenue quarter-to-quarter based on systems deliveryWeakness in X-ray systems demand persisting in Q4Automotive-related systems organic sales declineForeign exchange rate volatilityMacro disruptions and dynamic trade environment

Q&A highlights

Mike Halloran · Baird

Is strength in ETS semiconductor segment broadening beyond AI/data center to traditional electronics (auto, general electronics)? What are the right margin levels to model for 2026, particularly given strong medical segment performance this quarter?

Semiconductor strength remains concentrated in AI/cloud computing applications. Automotive stabilizing and general electronics growing slower than semiconductors. Revenue split: 50% semiconductor, 15% automotive, rest electronics. Medical segment margins at 40%+ this quarter are not sustainable; upper 30s is the right level, driven by portfolio changes and operational tailwinds. ETS and IPS margins represent appropriate jump-off points. Divestiture expected to improve segment margins by ~100 basis points.

50% of revenues from semiconductor space15% from automotiveMedical margins at 40%+ not sustainable; target upper 30s~100 basis point margin improvement from divestiture

Mitch Moran · KeyBank

Within IPS, polymer processing weakness is masking stable growth elsewhere. What are expectations for polymer processing vs. the rest of the business in 2026? What is the order intake and backlog trajectory?

Polymer processing has bottomed out in order entry and backlog. Expectations are for improvement from the trough, not further deterioration. The weakness is not expected to continue dragging on IPS. For ATS Q1, healthy growth implied is driven by good underlying stable demand in semiconductors, electronics, automotive, and general electronics, plus favorable year-over-year comps from slow Q1 start last year. Stronger backlog position entering 2026 vs. prior year start.

Polymer processing at the bottom with improving order entry and backlogNot expecting further deterioration in polymer processingQ1 ATS growth driven by favorable YoY comps plus ongoing demandStronger backlog position entering 2026 vs. last year

Matt Somerville · DA Davidson

Why is X-ray inspection growth decoupled from broader AI/cloud-driven semiconductor growth? Are new product launches and technology transitions driving upside? Also, what is the M&A strategy and capital allocation philosophy at current valuation?

X-ray has solid automotive exposure, which differs from broader semiconductor trends. Company is excited about new product launches. X-ray benefits from advanced chip architectures with both logic and memory, where acoustic is used for memory and X-ray for logic. Technology transition underway in testing; new technologies currently being tested but likely impact in 2027, not 2026. X-ray in good position to contribute to ATS growth in 2026. M&A strategy remains focused on highly differentiated, strategically and financially disciplined acquisitions. Pipeline is healthy but 2025 saw no actionable deals meeting both strategic and financial criteria. Capital allocation is balanced between share buybacks and acquisitions. Stock remains actionable for buybacks at $250 range with recent authorization increase providing near-term coverage.

X-ray exposure to automotive explains decoupling from semiconductor growthNew product launches underwayNew testing technologies currently in development; expected impact in 2027, not 2026M&A pipeline is healthy but requires meeting both strategic and financial criteria

Andrew Buscalia · BNP

If tougher markets have troughed, why does low-end guidance assume minimal growth? What risks exist that warrant a conservative low-end case? How does management perceive IPS sensitivity to industrial production and outlook for industrial factors recovery in 2026?

Guidance range reflects planning for both upside and downside scenarios. Q1 strong, first quarter implied in guidance. Downside case contemplates 'something happens' but management sees no current indicators of downsides. As the year plays out, guidance will be updated. For IPS in 2025, the segment was weighed down by polymer processing weakness and automotive decline, which masked core IPS progress. Precision Ag grew double-digit in 2025 and is expected to continue strong, with good order entry and backlog visibility. Automotive has troughed and stabilized; any recovery is upside. IPS business expected to achieve GDP-plus growth in 2026 with polymer processing and automotive recovery providing upside. Aftermarket parts (55-56% of IPS revenue) expected to see stable demand.

Q1 expected to be strong, driving upsideDownside case more hypothetical than based on current indicatorsPolymer processing troughed with expected nominal growthPrecision Ag grew double-digit in 2025; European/South American business

Brad Hewitt · Wolf Research

Can you quantify sequential backlog trends and provide business-level detail? Is normal seasonality expected in 2026 for both revenue/EBITDA and organic growth split between H1 and H2?

Backlog up 5% year-over-year but down sequentially, which is normal given Q1 is seasonally the lowest quarter due to holidays and year-end timing. Expecting normal seasonality in 2026, with Q1 being the lowest quarter and sequential improvement throughout the year. Chinese New Year is in Q2 this year with nominal impact. Organic growth expected to follow similar patterns in H1 vs. H2.

Backlog up 5% YoY but down sequentially (normal for Q1)Q1 historically lowest quarter due to seasonalityNormal seasonality expected for 2026Chinese New Year in Q2 2026 with nominal impact

Answers to last quarter's watch list

IPS Q4 organic acceleration from +0.5% — IPS printed -1.5% YoY in Q4, actually decelerating versus Q3. The "trough" call was not validated by inflection — only by the absence of further deterioration. Management's Q&A response was that polymer processing has bottomed and IPS will target "GDP-plus growth" in FY26 with polymer processing and automotive recovery as upside.

Resolved negatively

Q4 ATS organic growth vs tough comp; -3% as the line in the sand — ATS printed -3.6% YoY, marginally worse than the implied flat-to-down warning and right at the edge of the "lumpy vs structural" threshold. Management attributed it to systems delivery timing and reiterated that semiconductor exposure (50% of ATS) supports the forward case.

Resolved negatively

Final FY2025 prints vs "slightly below / slightly above midpoint" — Revenue landed at the low end of the FY range (worse than "slightly below midpoint" framing), and FY EPS of $10.24 came in below the midpoint, not above. The Q4 quarter beat on EPS but the FY trajectory undershot last quarter's commitment.

Resolved negatively

IPS Q4 EBITDA margin showing the >$15M restructuring run-rate — IPS Q4 EBITDA margin printed 38%, healthy and consistent with the segment's historical level, suggesting cost actions are flowing through. Management did not explicitly break out the restructuring savings in the press-release-only disclosure.

Continue monitoring

CDMO close confirmation and ~100bps medical margin accretion — Medical Q4 EBITDA margin printed 39.8% (above the "upper 30s" sustainable level management cited in Q&A). DA Davidson Q&A confirmed the ~100bps divestiture-driven margin uplift is still the expectation for FY26.

Resolved positively

Backlog trajectory — Backlog of ~$600M, up 5% YoY but down sequentially. Management framed the sequential decline as normal Q1 seasonality rather than weakening demand. The YoY +5% gives the "stronger entering FY26" claim some support but does not by itself confirm the organic recovery case.

Continue monitoring

M&A pace given Atrion accretion and YTD buybacks — Zero acquisitions closed in 2025; management cited no deals meeting both strategic and financial criteria. Buybacks now positioned as the actionable near-term lever at ~$250. The capital deployment cadence shifted decisively toward repurchases. Status: Resolved negatively (for M&A); capital return story intact

What to watch into next quarter

Whether Q1 ATS growth materializes given management's "Q1 strong" framing — they explicitly attributed it partly to favorable YoY comps off a soft Q1 FY2025 base, so the underlying demand signal is muddier than headline growth will suggest

IPS Q1 organic growth — a third consecutive quarter at or below zero would force management to walk back the "headwinds behind us" framing

Medical segment EBITDA margin post-CDMO close — does the segment settle into the "upper 30s" range management called out, and does the ~100bps divestiture accretion show up cleanly in Q1

FY26 revenue guide updates — if Q1 prints strong and management does not raise the FY range, the +1–6% guide is signaling caution about H2 that wasn't visible in the prepared remarks tone

Backlog quality — another sequential decline in Q1 (even if seasonally explained) combined with the YoY+5% moving toward zero would invalidate the "stronger entering FY26" thesis

Buyback pace at the stated ~$250 actionable level — management explicitly framed the stock as actionable; meaningful Q1 repurchase activity would confirm capital allocation has shifted away from M&A

Sources

Nordson Corporation Q4 FY2025 press release — https://www.sec.gov/Archives/edgar/data/72331/000007233125000138/ndsn-20251213xex991.htm
Nordson Corporation Q4 FY2025 earnings call transcript

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.